Gynuity Health Projects

Resources

Use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: Evidence from Uzbekistan.

This study sought to assess the feasibility and acceptability of introducing medical abortion up to 63 days’ LMP in Uzbekistan, with the option of home administration of misoprostol. Findings include a high success rate and high acceptability among participants. In addition, almost all women chose to administer the misoprostol at home.

Access the full abstract at The European Journal of Contraception and Reproductive Health Care. 2013 Apr;18(2):104-11.

  • Topic: Medical Abortion
  • Type: Staff Publication
  • Author: Raghavan, S., Tsereteli, T., Kamilov, A., Kurbanbekova, D., Yusupov, D., Kasimova, F., Jymagylova, D., Winikoff, B.
  • Published: April 2013